Head to Head Contrast: Artivion (AORT) vs. The Competition

Artivion (NYSE:AORT – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Artivion to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Artivion and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Artivion $481.88 million $9.77 million -50.56
Artivion Competitors $1.90 billion $136.32 million 5.94

Artivion’s rivals have higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

86.4% of Artivion shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Artivion has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Artivion’s rivals have a beta of 2.53, suggesting that their average share price is 153% more volatile than the S&P 500.

Profitability

This table compares Artivion and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Artivion -3.65% 5.12% 2.36%
Artivion Competitors -191.42% -197.86% -21.83%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Artivion and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artivion 1 0 6 0 2.71
Artivion Competitors 4330 10559 18358 840 2.46

Artivion currently has a consensus price target of $39.00, indicating a potential upside of 114.29%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.64%. Given Artivion’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Artivion is more favorable than its rivals.

Summary

Artivion beats its rivals on 7 of the 13 factors compared.

Artivion Company Profile

(Get Free Report)

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.